Market Overview

Susan G. Komen®-Funded Research Reveals How Obesity Impacts Breast Cancer Treatment and Patient Outcomes


Susan G. Komen®, the world's largest nonprofit funder of breast cancer
research, today hailed work led by Komen researcher Dr. Elizabeth
Wellberg and team at the University of Colorado Cancer Center which
sheds new light on how obesity can negatively impact treatment and lead
to poorer outcomes for postmenopausal women with estrogen receptor (ER+)
breast cancer.

This new laboratory research, published today in The Journal
of Clinical Investigation
, shows that obesity promotes the way ER+
tumors progress and become resistant to endocrine therapy through a
protein called FGFR1. Though more research is needed, targeting FGFR1
could help reverse the negative effects that obesity has on treatment
response, ultimately improving survival for ER+ breast cancer patients
who may be overweight or obese at the time of treatment.

"Dr. Wellberg's work shows us that to deliver effective breast cancer
treatment and improve outcomes, it's important to look at the full
picture of a patient's health, and not just the characteristics of their
tumor," said Victoria Wolodzko, SVP of Mission at Komen. "This work not
only provides a treatment target (in FGFR1) which may someday help women
and men facing ER+ breast cancer, but supports a growing body of
evidence that weight loss could play a critical role in breast cancer
treatment in the future."

"Dr. Wellberg exemplifies why Komen continues to invest in early career
breast cancer researchers with promising ideas that will help us achieve
our goal of reducing the current number of breast cancer deaths in the
U.S. by half by 2026," said Wolodzko.

To date, Komen has invested more than $956 million in breakthrough
breast cancer research – the largest nonprofit breast cancer research
investment outside of the U.S. government. Read more about this
groundbreaking research from University
of Colorado Cancer Center

About Susan G. Komen®

Susan G. Komen is the world's largest breast cancer organization,
funding more breast cancer research than any other nonprofit outside of
the federal government while providing real-time help to those facing
the disease. Komen has set a Bold Goal to reduce the current number of
breast cancer deaths by 50 percent in the U.S. by 2026. Since its
founding in 1982, Komen has funded more than $956 million in research
and provided more than $2.1 billion in funding to screening, education,
treatment and psychosocial support programs serving millions of people
in more than 60 countries worldwide. Komen was founded by Nancy G.
Brinker, who promised her sister, Susan G. Komen, that she would end the
disease that claimed Suzy's life. That promise has become Komen's
promise to all people facing breast cancer. Visit
or call 1-877 GO KOMEN. Connect with us on social at

View Comments and Join the Discussion!